Innovative Cyclospora Diagnostic Technologies and Emerging Markets

November 2012 | 191 pages | ID: I5B810CFAF8EN
Venture Planning Group

Abstracts

The report contains 191 pages, 7 tables and presents a detailed analysis of the Cyclospora diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cyclospora definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments:

• Hospitals
• Commercial/Private Labs
• Physician Offices
• Public Health Labs

For each country, in addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Cyclospora tests.

Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.

Contains 191 pages and 7 tables

Contents

I. INTRODUCTION

II. CYCLOSPORA WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Background
B. Diagnostic Tests
C. Vaccines and Drugs
D. Emerging Diagnostic Technologies
  1. Molecular Diagnostics
  2. Monoclonal Antibodies
  3. Immunoassays
  4. Differential Light Scattering
  5. Information Technology
  6. Artificial Intelligence
  7. Liposomes
  8. Flow Cytometry
  9. Chromatography
  10. Diagnostic Imaging
  11. Gel Microdroplets
  12. Other

III. FRANCE: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

IV. GERMANY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

VI. JAPAN: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

VII. SPAIN: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

VIII. UK: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

IX. USA: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

X. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation

XI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

XII. COMPETITIVE ASSESSMENTS

Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Enzo Biochem
Fujirebio
Gen-Probe
Hologic
ID Biomedical
Innogenetics/Solvay
Kreatech
Life Technology
Lonza
Nanogen/Elitech
Novartis Diagnostics
Ortho-Clinical Diagnostics
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens
Takara Bio
Thermo Fisher
Wallac
Wako

List Of Tables

LIST OF TABLES

France
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment
Germany
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment
Italy
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment
Japan
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment
Spain
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment
U.K.
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment
U.S.A.
Cyclospora Test Volume and Diagnostics Sales Forecast by Market Segment